Jabil (NYSE:JBL) division Jabil Healthcare announced a collaboration agreement with E3D, giving it access to E3D’s auto-injector.
The agreement with the global drug delivery device company, which is a member of the Elcam Medical Group, gives Jabil exclusive rights to develop a high-volume reusable autoinjector and connected variants, according to a news release.
St. Petersburg, Fla.-based Jabil Healthcare is now capable of developing connected auto-injectors for a range of dosing volumes and patient-centric benefits with the ultimate aim of creating a platform of these devices.
“Our collaboration with E3D enhances Jabil’s development of pharmaceutical solutions that move us into the future of connected, digital devices that are more intuitive, economical and sustainable,” Jabil Healthcare VP of pharmaceutical delivery systems James O’Gorman said in the release. “This is an exciting expansion of our relationship with E3D that will benefit our market offering and healthcare customers alike.”
“As a leader in the healthcare arena, Jabil Healthcare is the perfect partner for us and for a drug delivery market that requires the highest levels of competence, experience and scale in manufacturing,” added E3D GM Tsachi Shaked. “Our complementary expertise in electronics, manufacturing and data analysis is the type of collaboration that should help speed advances and adoption of digital health technologies.”
